GlassScriptPhysician profile
Susan A Gallagher
NPI 1083694293
$317.98
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $90.29 · 2021: $126.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $171.42 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $23.13 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.43 | 2019 | |
| Lilly USA, LLC | $22.29 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.17 | 2021 | |
| Eisai INC. | $16.25 | 2020 | |
| Amarin Pharma, INC. | $15.12 | 2020 | |
| Clarus Therapeutics INC. | $14.54 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.63 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Gallagher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.